This week in Washington: Andrea Palm’s nomination for HHS Deputy Secretary Advances out of Senate Finance Committee, Chiquita Brooks-LaSure’s nomination deadlocked.

House

House Republicans Introduce Drug Pricing Legislation

On April 21, Reps. Cathy McMorris Rodgers (R-WA), Kevin Brady (R-TX) and Virginia Foxx (R-NC) introduced the Lower Costs, More Cures Act (H.R. 19), which aims to

This week in Washington: House and Senate return from congressional work period.

House

House Energy and Commerce Hearing on Substance Use to Consider 11 Bills

On April 14 at 10:30 a.m., the House Energy and Commerce Committee Subcommittee on Health will hold a hearing titled “An Epidemic within a Pandemic: Understanding Substance Use and Misuse

Stethoscope on laptop keyboard

About 475 million people worldwide have received a COVID-19 vaccine, and a return to normalcy draws closer. What remains unclear, however, is how state and federal governments will regulate and reimburse for telehealth when temporary telehealth policies expire at the end of the public health emergency.

Read on for a summary of proposed federal regulatory

This week in Washington: Budget reconciliation package passes and is signed into law; Becerra’s nomination for HHS secretary advances in the Senate.

House

House Passes Final Budget Reconciliation Bill
On March 10, the House passed the final version of the Senate budget reconciliation bill. One Democrat voted with the Republicans, who were united against the

On March 6, the U.S. Senate narrowly passed a $1.9 trillion bill to provide for COVID-19 financial relief, testing, treatment and vaccination. Because the Senate version of the plan differs from the version the U.S. House of Representatives passed last week, the measure now returns to the House to reconcile differences before President Joe Biden

This week in Washington: Budget reconciliation goes back to the House with changes for vote on Tuesday.

House

340B: 266 House Legislators Want Fines for Drug Companies

Two hundred sixty-six members of the House of Representatives have told the Department of Health and Human Services that HHS should fine drug companies that deny 340B discounts